M

MASARYK P

Last name: MASARYK P

2022 (v1)

Publication

Metadata-only

Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.

Hartman L da Silva JAP Buttgereit F

No description

Uploaded on: January 31, 2024
2023 (v1)

Publication

Metadata-only

Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial

Almayalım AAH Boers M Hartman L

Objective: The randomised placebo-controlled GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) trial evaluated the benefits and harms of prednisolone 5 mg/day added to standard care for 2 years in patients aged 65+ years with rheumatoid arthritis (RA). Here, we studied disease activity, flares and possible adrenal insufficiency after...

Uploaded on: February 13, 2024
2022 (v1)

Publication

Metadata-only

Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.

Hartman L El Alili M Cutolo M

No description

Uploaded on: February 14, 2024
2022 (v1)

Publication

Metadata-only

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.

Boers M Hartman L Opris-Belinski D

No description

Uploaded on: February 14, 2024